NCT03934606Completed
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model: A Pilot Study of Patient Outcomes
Source: ClinicalTrials.gov · Last updated 10 Apr 2025
Brief summary (registry, in English)
To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study will be used to inform the strategies used by the Clinical Risk Evaluation Program (CREP) Genetic Counelors (CGS) and GI/GU physicians to deliver genetic testing and return genetic risk information to patients with prostate or pancreatic cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1488 (actual)
- First submitted
- 13 Feb 2019
- Start date
- 1 Jan 2018
- Primary completion date
- 31 Jan 2025
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Prostate cancer, Pancreatic cancer
- NCT number
- NCT03934606
What you commit to
- Study type: Observational
- Participants enrolled: 1488
- From 1 Jan 2018 to the primary completion date, 31 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • Patients who do not or will not receive their ongoing cancer care at Penn
- Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.
- Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
Who the study is looking for
- • Penn patient age 18 years or older.
- Diagnosed with prostate cancer or pancreas cancer.
- Deemed to be clinically appropriate for multiplex genetic testing by their Urologic Cancer Program (GU) physician or Gastrointestinal Cancer Program (GI) physician at the Abramson Cancer
- Agreed to receive clinical multiplex genetic testing from their physician.
- English-fluent; the surveys were designed and validated in English and are not currently available in other languages.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn Medicine, University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.